Head-To-Head Analysis: ENDRA Life Sciences (NDRA) & Its Competitors

Share on StockTwits

ENDRA Life Sciences (NASDAQ: NDRA) is one of 48 publicly-traded companies in the “Electromedical equipment” industry, but how does it compare to its competitors? We will compare ENDRA Life Sciences to similar businesses based on the strength of its earnings, risk, institutional ownership, analyst recommendations, profitability, dividends and valuation.

Risk and Volatility

ENDRA Life Sciences has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, ENDRA Life Sciences’ competitors have a beta of 1.40, indicating that their average share price is 40% more volatile than the S&P 500.

Insider & Institutional Ownership

17.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 43.9% of shares of all “Electromedical equipment” companies are held by institutional investors. 11.4% of ENDRA Life Sciences shares are held by company insiders. Comparatively, 15.9% of shares of all “Electromedical equipment” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares ENDRA Life Sciences and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ENDRA Life Sciences N/A -326.97% -233.06%
ENDRA Life Sciences Competitors -277.66% -137.74% -18.75%

Analyst Recommendations

This is a breakdown of current ratings and price targets for ENDRA Life Sciences and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ENDRA Life Sciences 0 0 2 0 3.00
ENDRA Life Sciences Competitors 246 678 1286 61 2.51

As a group, “Electromedical equipment” companies have a potential upside of 25.45%. Given ENDRA Life Sciences’ competitors higher probable upside, analysts clearly believe ENDRA Life Sciences has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares ENDRA Life Sciences and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
ENDRA Life Sciences $10,000.00 -$9.80 million -0.91
ENDRA Life Sciences Competitors $1.21 billion $130.98 million 20.83

ENDRA Life Sciences’ competitors have higher revenue and earnings than ENDRA Life Sciences. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

ENDRA Life Sciences competitors beat ENDRA Life Sciences on 10 of the 13 factors compared.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. It also offers Nexus-128 system that combines light-based thermos-acoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. ENDRA Life Sciences Inc. has collaborative research agreement with General Electric Company. The company was incorporated in 2007 and is based in Ann Arbor, Michigan.

Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SSE PLC/S  Receives Consensus Rating of “Hold” from Brokerages
SSE PLC/S Receives Consensus Rating of “Hold” from Brokerages
Zacks: Analysts Expect 3D Systems Co.  to Announce -$0.04 Earnings Per Share
Zacks: Analysts Expect 3D Systems Co. to Announce -$0.04 Earnings Per Share
James Hardie Industries plc  Receives Consensus Rating of “Hold” from Brokerages
James Hardie Industries plc Receives Consensus Rating of “Hold” from Brokerages
Zacks: Brokerages Anticipate CenterPoint Energy, Inc.  to Announce $0.33 EPS
Zacks: Brokerages Anticipate CenterPoint Energy, Inc. to Announce $0.33 EPS
Zacks: Brokerages Anticipate Community Health Systems  to Announce -$0.49 Earnings Per Share
Zacks: Brokerages Anticipate Community Health Systems to Announce -$0.49 Earnings Per Share
SYSCO Co.  Sees Significant Decrease in Short Interest
SYSCO Co. Sees Significant Decrease in Short Interest


 
© 2006-2019 Zolmax.